# Lifecore Biomedical, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Lifecore Biomedical, Inc). ## Overview Lifecore Biomedical is a U.S.-based contract development and manufacturing organization that makes and fills complex sterile injectable pharmaceutical products and medical device products under contract for other companies. The business is centered in Chaska, Minnesota and combines hyaluronic acid manufacturing with aseptic fill-finish, formulation, and development services across syringes, vials, and cartridges. ## Products & services • Aseptic fill-finish for sterile injectables • Contract development for complex formulations • Pharmaceutical-grade hyaluronic acid (HA) manufacturing • Clinical and commercial manufacturing services • Analytical, validation, and process-scale-up services • Packaging and supply-chain support for injectable products - **Contract development and manufacturing** (60%) — Development, tech transfer, and commercial production of sterile injectable products for customers. - **Aseptic fill-finish** (25%) — Aseptic filling of injectable drug and device products into syringes, vials, and cartridges. - **Hyaluronic acid API** (10%) — Non-animal-sourced hyaluronic acid produced in bulk and for formulated injectable products. - **Development services** (5%) — Analytical, formulation, validation, and scale-up services that support product launches. - Aseptic fill-finish for sterile injectables - Contract development for complex formulations - Pharmaceutical-grade hyaluronic acid (HA) manufacturing - Clinical and commercial manufacturing services - Analytical, validation, and process-scale-up services - Packaging and supply-chain support for injectable products ## Customers Lifecore sells primarily to biopharmaceutical and biotechnology companies that need a contract partner for development and sterile manufacturing of injectable products. It also serves customers in medical-device and specialty healthcare markets, including programs tied to ophthalmic, orthopedic, wound care, aesthetics, and drug-delivery applications. Customers choose Lifecore for its ability to take a product from development through commercial fill-finish while managing regulatory and quality requirements. Academic and corporate research customers also appear in the pipeline for certain HA-related and development work. - **Biopharmaceutical companies** (primary) — Buy development, tech transfer, and commercial fill-finish for injectable drug programs. - **Biotechnology companies** (primary) — Buy clinical and early commercial manufacturing for novel injectable therapies. - **Medical device and combination-product customers** (secondary) — Buy aseptic manufacturing and fill-finish for syringe, vial, and cartridge products. - **HA application developers** (secondary) — Buy HA raw material and formulation support for ophthalmic, orthopedic, and specialty uses. - **Academic and corporate research customers** (emerging) — Buy development services and material supply for exploratory HA and injectable work. - Biopharma sponsors needing sterile injectable CDMO capacity - Biotech companies advancing clinical-stage programs to launch - Medical device and combination-product customers - HA-based therapy developers in ophthalmic and orthopedic uses - Research customers exploring new HA applications ## Geography Lifecore is headquartered and operates in the United States, with manufacturing concentrated in its cGMP facilities in Chaska, Minnesota. Its customer base is global, supported by certifications and regulatory experience in Europe, Japan, Brazil, and other major markets. The business is exposed to cross-border regulatory requirements because many customer products are sold internationally and must clear multiple health authorities. Geography matters mainly through where the plants sit, where customers launch products, and which regulators oversee each program. - Headquartered in Chaska, Minnesota - Manufacturing centered in three cGMP facilities - Serves customers globally across multiple markets - Regulatory certifications include Europe, Japan, and Brazil - International customer programs add cross-border compliance exposure ## Strategy Lifecore's strategy is to expand its CDMO pipeline by winning new sterile injectable programs, converting development work into commercial manufacturing, and broadening beyond its traditional HA base. It is also focused on improving manufacturing capacity, quality systems, and operational efficiency so that it can handle more complex programs and support higher customer demand. The company uses its vertically integrated model to offer a broader service package, from raw material supply through aseptic fill-finish and supply-chain responsibility. That combination is meant to make it a more durable partner for sponsors needing speed, regulatory discipline, and technical depth. - **Win new development and commercial programs** (short-term) — A broader pipeline increases future manufacturing volume and customer diversification. - **Convert development projects into commercial supply** (medium-term) — Commercialized programs create recurring manufacturing demand and deeper customer relationships. - **Expand aseptic fill-finish capacity** (medium-term) — More capacity allows the company to pursue larger and more complex injectable opportunities. - **Improve operational efficiency and quality** (short-term) — Better execution supports sponsor confidence, lower unit costs, and stronger manufacturing reliability. - Grow the business-development pipeline with new injectable programs - Move more projects from development into commercial supply - Expand aseptic filling capacity for complex and viscous products - Broaden the mix beyond traditional HA-centric programs - Use quality and regulatory track record to win sponsor trust - Improve productivity and process control across operations ## Risks Lifecore is exposed to regulatory and manufacturing risks because it produces sterile injectable products under cGMP requirements and depends on passing inspections by the FDA and other agencies. It also relies on customers obtaining and keeping product approvals, so delays, recalls, or launch failures at sponsor companies can reduce demand for its services. The company faces customer concentration, execution, and financing risk common to CDMOs, especially when adding complex programs that require capital, validation, and reliable throughput. Competition for specialized sterile-fill capacity and any quality issue at the plant level could materially affect future business wins and customer retention. - **cGMP compliance and regulatory inspection risk** [high] — Sterile manufacturing is heavily regulated and adverse findings can interrupt production or trigger remediation. - **Customer product approval dependence** [high] — Revenue depends on sponsors obtaining approvals for the products Lifecore manufactures for them. - **Manufacturing quality or contamination events** [high] — Aseptic fill-finish requires strict control; defects can lead to recalls, downtime, or lost customers. - **Customer concentration and sponsor funding risk** [medium] — Program delays or sponsor funding shortfalls can reduce orders and backlog conversion. - **Execution risk on new capacity and programs** [medium] — Complex fill-finish lines and new site transfers require validation, staffing, and process discipline. - cGMP or inspection findings could disrupt manufacturing or require remediation - Customer regulatory delays can postpone launch and reduce program revenue - Sterile injectables carry contamination and recall risk - New program execution can be delayed by validation or scale-up issues - CDMO demand depends on sponsor funding and outsourcing decisions ## Accounting Revenue recognition is important because Lifecore sells a mix of development services, site transfers, and commercial manufacturing work, which can differ in timing and completion criteria. The business also likely uses significant estimates for contract obligations, inventory, and customer program progress, and it may face quarter-to-quarter swings as projects move through validation or commercialization. Lease accounting, fixed-asset capitalization for capacity investments, and impairment testing for long-lived assets can also influence reported results. Because the company has had financing transactions and preferred stock items, equity and debt accounting judgments are also relevant to the financial statements. - **Revenue recognition** — Can shift revenue between periods as programs progress - **Cost capitalization and depreciation** — Affects gross margin and operating expense trends - **Inventory and work-in-process estimates** — Can affect margin and inventory valuation - **Impairment testing** — Could create non-cash charges - **Financing and equity accounting** — Affects leverage presentation and earnings per share - Revenue recognition across development and manufacturing contracts - Timing differences between clinical work and commercial production - Inventory, work-in-process, and program-specific cost estimates - Capitalized equipment and plant investment depreciation - Impairment and recoverability of long-lived manufacturing assets - Preferred stock, debt, and financing-related accounting --- *Last updated: 2026-09-28T10:45:35.651229+00:00*